Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022708 | 0.78 | ALDH1A1 (0.38) | ALDH1A1GABRA1GABRB2TDP1MEN1 | |
| SCHEMBL4088533 | 0.77 | LMNA (0.48) | RIPK1ALDH1A1GABRA1GABRB2TDP1 | |
| SCHEMBL320588 | 0.77 | GABRA1 (0.50) | ALDH1A1GABRA1GABRB2TDP1MEN1 | |
| SCHEMBL8431195 | 0.75 | ERN1 (0.50) | RIPK1ALDH1A1GABRA1GABRB2TDP1 | |
| SCHEMBL1275278 | 0.75 | RIPK1 (0.44) | RIPK1GABRA1GABRB2LMNATHRA | |
| SCHEMBL6685097 | 0.73 | RIPK1 (0.56) | RIPK1GABRA1GABRB2LMNAESR1 | |
| SCHEMBL10351355 | 0.71 | GABRA1 (0.39) | ALDH1A1GABRA1GABRB2TDP1MEN1 | |
| SCHEMBL2082859 | 0.71 | NPC1 (0.39) | RIPK1ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL19860487 | 0.71 | RIPK1 (0.35) | RIPK1 | |
| SCHEMBL6038253 | 0.70 | ALDH1A1 (0.42) | ALDH1A1GABRA1GABRB2TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645914-B2 | Method for the telomerization of non-cyclic olefins | EVONIK OXENO GMBH (DE) | 2010-01-12 | — | — | US | disclosed |
| US-20070213574-A1 | METHOD FOR THE TELOMERIZATION OF NON-CYCLIC OLEFINS | EVONIK DEGUSSA GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213574-A1 | METHOD FOR THE TELOMERIZATION OF NON-CYCLIC OLEFINS | TELO2, PCNA, TERT | RIPK1 4235/4885ALDH1A1 3690/4885GABRA1 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.